Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors

Breast Journal

Volumn 20, Issue 1, 2014, Pages 22-28

  Brown, Justin C ^a   Mao, Jun J ^a,b   Stricker, Carrie ^a,b   Hwang, Wei Ting ^a,b   Tan, Kay See ^a   Schmitz, Kathryn H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

behavior; exercise; physical function; psychosocial; symptoms

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BODY MASS; BREAST CANCER; CANCER SURVIVOR; CROSS-SECTIONAL STUDY; EXERCISE; FEMALE; FOLLOW UP; HUMAN; LEG; MAJOR CLINICAL STUDY; MIDDLE AGED; MUSCULOSKELETAL DISEASE; PHYSICAL ACTIVITY; TREATMENT OUTCOME;

BEHAVIOR; EXERCISE; PHYSICAL FUNCTION; PSYCHOSOCIAL; SYMPTOMS;

AGED; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; EXERCISE; FEMALE; HUMANS; MIDDLE AGED; MOTOR ACTIVITY; MULTIVARIATE ANALYSIS; MUSCULOSKELETAL DISEASES; QUALITY OF LIFE; SELF REPORT; SURVIVORS;

EID: 84892821775     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12202     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Altundag K, Ibrahim NK,. Aromatase inhibitors in breast cancer: an overview. Oncologist 2006; 11: 553-62.
3. Howell A, Cuzick J, Baum M, et al,. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-2.
4. Goss PE, Ingle JN, Martino S, et al,. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-802.
5. Jakesz R, Jonat W, Gnant M, et al,. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-62.
6. Bevers TB, Anderson BO, Bonaccio E, et al,. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 2009; 7: 1060-96.
7. Burstein HJ,. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007; 16: 223-34.
8. Donnellan PP, Douglas SL, Cameron DA, Leonard RC,. Aromatase inhibitors and arthralgia. J Clin Oncol 2001; 19: 2767.
9. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A,. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26: 556-62.
10. Stricker CT, Palmer SC, Demichele A, Mao JJ,. Understanding premature discontinuation of aromatase inhibitor (AI) therapy in postmenopausal breast cancer survivors. J Clin Oncol 2010; 28 (15Suppl): 458s.
11. Winters L, Habin K, Flanagan J, Cashavelly BJ,. "I feel like I am 100 years old!" managing arthralgias from aromatase inhibitors. Clin J Oncol Nurs 2010; 14: 379-82.
12. Thorne C,. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol 2007; 14 (Suppl 1): S11-9.
13. Mangani I, Cesari M, Kritchevsky SB, et al,. Physical exercise and comorbidity. Results from the Fitness and Arthritis in Seniors Trial (FAST). Aging Clin Exp Res 2006; 18: 374-80.
14. Baillet A, Zeboulon N, Gossec L, et al,. Efficacy of cardiorespiratory aerobic exercise in rheumatoid arthritis: meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken) 2010; 62: 984-92.
15. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA,. Physical activity and survival after breast cancer diagnosis. JAMA 2005; 293: 2479-86.
16. Irwin ML, Alvarez-Reeves M, Cadmus L, et al,. Exercise improves body fat, lean mass, and bone mass in breast cancer survivors. Obesity (Silver Spring) 2009; 17: 1534-41.
17. Ganz PA, Coscarelli A, Fred C, Kahn B, Polinsky ML, Petersen L,. Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Res Treat 1996; 38: 183-99.
18. Mao JJ, Stricker C, Bruner D, et al,. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 2009; 115: 3631-9.
19. Mao JJ, Su HI, Feng R, et al,. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 2011; 13: R8.
20. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW,. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 1833-40.
21. Sautner J, Andel I, Rintelen B, Leeb BF,. Development of the M-SACRAH, a modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands). Rheumatology (Oxford) 2004; 43: 1409-13.
22. Gummesson C, Ward MM, Atroshi I,. The shortened disabilities of the arm, shoulder and hand questionnaire (QuickDASH): validity and reliability based on responses within the full-length DASH. BMC Musculoskelet Disord 2006; 7: 44.
23. Hagstromer M, Oja P, Sjostrom M,. The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr 2006; 9: 755-62.
24. Schmitz KH, Courneya KS, Matthews C, et al,. American college of sports medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010; 42: 1409-26.
25. Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH,. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv 2010; 4: 87-100.
26. Shih M, Hootman JM, Kruger J, Helmick CG,. Physical activity in men and women with arthritis National Health Interview Survey, 2002. Am J Prev Med 2006; 30: 385-93.
27. Younus J, Kligman L,. Management of aromatase inhibitor-induced arthralgia. Curr Oncol 2010; 17: 87-90.
28. Din OS, Dodwell D, Wakefield RJ, Coleman RE,. Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat 2010; 120: 525-38.
29. ClinicalTrials.gov. aromatase inhibitors and arthralgia. Available at: http://clinicaltrials.gov/ct2/results?term=aromatase+inhibitors+and+arthralgia (accessed June 4, 2012).
30. Theis KA, Helmick CG, Hootman JM,. Arthritis burden and impact are greater among U.S. women than men: intervention opportunities. J Womens Health (Larchmt) 2007; 16: 441-53.
31. Khan QJ, Reddy PS, Kimler BF, et al,. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119: 111-8.
32. Mao JJ, Bruner DW, Stricker C, et al,. Feasibility trial of electroacupuncture for aromatase inhibitor-related arthralgia in breast cancer survivors. Integr Cancer Ther 2009; 8: 123-9.
33. Crew KD, Capodice JL, Greenlee H, et al,. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 2010; 28: 1154-60.
34. Henry NL, Banerjee M, Wicha M, et al,. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer 2011; 117: 5469-75.
35. Dent SF, Gaspo R, Kissner M, Pritchard KI,. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat 2011; 126: 295-310.
36. Crew KD, Greenlee H, Capodice J, et al,. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007; 25: 3877-83.